ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 468
- Registration Number
- NCT01478607
- Locations
- 🇺🇦
Site: 806, Kyiv, Ukraine
🇺🇦Site: 802, Mykolayiv, Ukraine
🇵🇱Site: 954, Katowice, Poland
To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together
Phase 1
Completed
- Conditions
- Pharmacokinetics of MirabegronHealthy Subjects
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 28
- Registration Number
- NCT01478568
- Locations
- 🇫🇷
SGS Aster, Paris, France
To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol
Phase 1
Completed
- Conditions
- Pharmacokinetics of MirabegronHealthy Subjects
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 28
- Registration Number
- NCT01478490
- Locations
- 🇳🇱
PRA International (former Pharma Bio-Research), Zuidlaren, Netherlands
To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females
Phase 1
Completed
- Conditions
- PharmacokineticsHealthy Subjects
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 96
- Registration Number
- NCT01478503
- Locations
- 🇳🇱
Kendle Nederland, Utrecht, Netherlands
🇳🇱Pharma Bio Research, Zuidlaren, Netherlands
A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation
Phase 1
Completed
- Conditions
- Pharmacokinetics of MirabegronBioavailabilityHealthy Subjects
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 12
- Registration Number
- NCT01478529
- Locations
- 🇳🇱
Pharma Bio Research, Zuidlaren, Netherlands
A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Healthy SubjectsPharmacokinetics of YM178
- Interventions
- Drug: YM178 OCAS
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01476800
- Locations
- 🇺🇸
MDS Pharma Services (US) Inc., Lincoln, Nebraska, United States
Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 319
- Registration Number
- NCT01451203
Special Drug Use-Results Survey of Lipitor Tablets
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: atrovastatin
- First Posted Date
- 2011-10-05
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24050
- Registration Number
- NCT01446679
A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 21
- Registration Number
- NCT01442337
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸St. Vincent Medical Center, Los Angeles, California, United States
🇺🇸Sharp Memorial, San Diego, California, United States
Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy Volunteers
Phase 1
Completed
- Conditions
- Pharmacokinetics of ASP015KDrug InteractionsHealthy Subjects
- Interventions
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2011-09-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01430065
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath